# Philogen S.p.A. clinical trials: 49 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials with Philogen S.p.A. as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Philogen S.p.A.: 49 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/philogen-s-p-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 20, 2026 | NCT07600554 | A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer | Philogen S.p.A. | Phase 1 | Completed | Prostate Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600554) |
| May 5, 2026 | NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | Philogen S.p.A. | Phase 1 | Not yet recruiting | Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566897) |
| November 24, 2025 | NCT07245992 | A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis | Philogen S.p.A. | Phase 1 | Recruiting | Rheumatoid Arthritis (RA) | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245992) |
| November 14, 2025 | NCT07228442 | L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma | Philogen S.p.A. | Phase 2 | Recruiting | Locally Advanced Cutaneous Squamous Cell Carcinoma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228442) |
| November 13, 2025 | NCT07227870 | L19IL2/TNF in Patients With Basal Cell Carcinoma | Philogen S.p.A. | Phase 2 | Recruiting | Locally Advanced Basal Cell Carcinoma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227870) |
| November 12, 2025 | NCT07227350 | L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) | Philogen S.p.A. | Phase 2 | Recruiting | Locally Advanced Basal Cell Carcinoma | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227350) |
| August 13, 2025 | NCT07120984 | A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or... | Philogen S.p.A. | Phase 2 | Not yet recruiting | Glioma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07120984) |
| February 21, 2025 | NCT06840548 | A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer | Philogen S.p.A. | Phase 1 | Completed | Clear Cell Renal Cell Carcinoma (ccRCC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06840548) |
| February 21, 2025 | NCT06840535 | A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer | Philogen S.p.A. | Phase 1 | Completed | Prostate Cancer, Prostate Cancer Metastatic Disease, PSA Level Greater Than 0.2 | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06840535) |
| October 15, 2024 | NCT06640413 | A Study to Evaluate the Safety and Preliminary Signs of Efficacy of \[177Lu\]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a... | Philogen S.p.A. | Phase 1 | Recruiting | FAP | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06640413) |
| March 28, 2024 | NCT06336291 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | Philogen S.p.A. | Phase 2 | Active not recruiting | Glioblastoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06336291) |
| February 29, 2024 | NCT06284590 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma... | Philogen S.p.A. | Phase 2 | Recruiting | Melanoma Stage III, Melanoma Stage IV | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06284590) |
| March 27, 2023 | NCT05784597 | A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors | Philogen S.p.A. | Phase 1 | Completed | Breast Cancer, Colorectal Cancer, Oesophageal Cancer, Pancreas Adenocarcinoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05784597) |
| November 18, 2022 | NCT05622175 | Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment | Philogen S.p.A. | Phase 1 | Withdrawn | Rheumatoid Arthritis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05622175) |
| July 21, 2022 | NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer | Philogen S.p.A. | Phase 1/2 | Unknown | Non-small Cell Lung Cancer (NSCLC) | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05468294) |
| April 15, 2022 | NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients | Philogen S.p.A. | Phase 2 | Unknown | BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05329792) |
| March 31, 2022 | NCT05304663 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression | Philogen S.p.A. | Phase 1 | Withdrawn | Glioblastoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05304663) |
| February 1, 2021 | NCT04733183 | Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma | Philogen S.p.A. | Phase 2 | Active not recruiting | Soft Tissue Sarcoma | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04733183) |
| December 3, 2020 | NCT04650984 | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic... | Philogen S.p.A. | Phase 3 | Unknown | Soft Tissue Sarcoma | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04650984) |
| October 5, 2020 | NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression | Philogen S.p.A. | Phase 1/2 | Unknown | Glioblastoma | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04573192) |
| July 15, 2020 | NCT04471987 | Safety and Early Signs of Efficacy of IL12-L19L19. | Philogen S.p.A. | Phase 1 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04471987) |
| June 23, 2020 | NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma | Philogen S.p.A. | Phase 1/2 | Recruiting | Glioblastoma | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04443010) |
| April 27, 2020 | NCT04362722 | Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients | Philogen S.p.A. | Phase 2 | Unknown | Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04362722) |
| July 25, 2019 | NCT04032964 | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS | Philogen S.p.A. | Phase 1 | Unknown | Soft Tissue Sarcoma | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04032964) |
| December 19, 2018 | NCT03779230 | Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse | Philogen S.p.A. | Phase 1/2 | Completed | Glioma of Brain | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03779230) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 12 |
| Phase 2 | 16 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Recruiting | 9 |
| Terminated | 9 |
| Unknown | 8 |
| Active not recruiting | 3 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Melanoma | 9 |
| Glioblastoma | 4 |
| Breast Neoplasms | 4 |
| Arthritis, Rheumatoid | 4 |
| Neoplasm Metastasis | 4 |
| Carcinoma, Basal Cell | 4 |
| Sarcoma | 4 |
| Colorectal Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Prostatic Neoplasms | 2 |
| Carcinoma, Renal Cell | 2 |
| Neoplasms | 2 |
| Carcinoma, Merkel Cell | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Recurrence | 2 |
| Lymphoma | 1 |
| Lung Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
| Carcinoma, Squamous Cell | 1 |
| Sarcoma, Kaposi | 1 |
| Carcinoma | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Leiomyosarcoma | 1 |
| Glioma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Business management services in the United States](https://specstream.ai/data/businesses/business-management-services/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Seafood restaurants in the United States](https://specstream.ai/data/businesses/seafood-restaurants/united-states)
- [Commercial printers in the United States](https://specstream.ai/data/businesses/commercial-printers/united-states)
